These are anthracycline chemotherapy, human epidermal growth factor receptor 2 (HER-2) targeted therapies, VEGF inhibitors, combination of RAF and MEK inhibitors, multi-targeted kinase inhibitors for CML and multiple myeloma therapies (HFA-ICOS Cardio-Oncology cardiovascular risk assessment tool (cancercalc.com) Table 1.15 Here, ERBB2 is linked to plasma cell myeloma.